Biogen Inc (BIIB) - News Archive

Major Law Firms Alert Investors: Class Action Lawsuits Against Biogen, Charge Enterprises, and Fastly Deadlines LoomingNew York, June 9, 2024 Bragar Eagel & Squire, P.C., a nationally-recognized shareholder rights law f...

FDA Accepts Eisai s sBLA for LEQEMBI IV Maintenance Dosing Amidst Biogen s Market Challenges TOKYO and CAMBRIDGE, Mass., June 9, 2024 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) and Biogen Inc. (Nas...

Biogen Inc., a leading biopharmaceutical company, is currently facing a class action lawsuit and a decline in revenue. The company and certain officers have been named as defendants in the lawsuit, which was filed in th...

: This article outlines the collaboration between Biogen Inc. and Delta Flight Products to enhance air travel accessibility for passengers with reduced mobility. Additionally, it examines Biogen s financial performance...

In recent developments, Biogen Inc. has made significant strides in the field of drug discovery by receiving European Commission approval for two groundbreaking therapies. The first therapy, QALSODY (tofersen), is the f...

Biogen Faces Class Action Lawsuits for Securities Fraud and Reports Progress on Corporate Responsibility PrioritiesBiogen Inc. (Biogen), a renowned biotechnology company, is currently facing class action lawsuits relate...

Biogen Inc., a renowned biotechnology company operating in the pharmaceutical industry, finds itself in troubled waters as a class action lawsuit is filed against the company and certain officers. The lawsuit alleges vi...

Biogen Inc. Faces Turbulent Times: Class Action Lawsuit Amidst Declining Revenues and Market ShareIn a recent development, Gainey McKenna & Egleston announced the filing of a securities class action lawsuit against Biog...

Breaking News: Biogen to Acquire HI-Bio in $1.8 Billion Deal for Targeted TherapiesCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 22, 2024 - Biogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio), a...

CSIMarket.com In recent announcements, Biogen Inc. and Ionis Pharmaceuticals, Inc. have made significant decisions regarding their drug development programs. The termination of BIIB105 (ION541), an investigational antis...

Eisai and Biogen: Advancements and Controversies in Neurological Therapies CSIMarket.com presents a comprehensive overview of recent significant developments involving Eisai Co., Ltd. and Biogen Inc., two pivotal stakeh...

CAMBRIDGE, Mass., May 02, 2024 In the spirit of transparency and corporate sustainability, Cambridge-based American multinational biotechnology giant, Biogen Inc. (Nasdaq: BIIB) has released its 2023 Corporate Responsib...

In exciting news for the pharmaceutical industry, Biogen Inc. has recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for two of its...

Biogen Inc., a leading biopharmaceutical company, has recently announced significant interim biomarker data that further supports the potential benefits of SPINRAZA (nusinersen) in infants and toddlers with spinal muscu...

Biogen Inc. (Nasdaq: BIIB) has recently announced a groundbreaking development in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND). The Committee for Medicinal Products...

Biogen Receives European Commission Approval for SKYCLARYS (omaveloxolone) as the First Treatment for Friedreich s Ataxia, While ZURZUVAE (zuranolone) CIV Offers a Landmark Oral Treatment for Postpartum Depression in th...

In a recent announcement, Biogen Inc. revealed its strategic plans to reprioritize resources within the field of Alzheimer s disease (AD), aiming to drive growth in the near and long-term. The pharmaceutical giant will...

Revocation of Centralized Marketing Authorizations for TECFIDERA Generics: A Blow to Biogen Inc. and its Corporate CustomersCAMBRIDGE, Mass., Dec. 19, 2023 - Biogen Inc. (Nasdaq: BIIB) has recently faced a significant s...

CAMBRIDGE, Mass., Dec. 15, 2023 Biogen Inc., a leading biotechnology company, recently announced a significant milestone in the treatment of a rare neurodegenerative condition known as Friedreich s ataxia (FA). The Camb...

ZURZUVAE (zuranolone) CIV: A Groundbreaking Oral Treatment for Postpartum Depression, Now Available in the U.S.Biogen Inc s Corporate Customers Experience Cost and Revenue Fluctuations in Q3 2023Postpartum depression (P...